US Patent 11180482 Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors

Patent 11180482 was granted and assigned to Ariad Pharmaceuticals, Inc. on November, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

111804820

Patent Inventor Names

Yun Zhang0

Wei-Sheng Huang0

Willmen Youngsaye0

Xiaotian Zhu0

Erin Geno0

Date of Patent

November 23, 2021

Patent Application Number

164650730

Date Filed

November 29, 2017

Patent Primary Examiner

‌

Brian E McDowell

Patent abstract

The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11180482 Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API